---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-118989"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:05:04.485907+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics CFO Jeffrey Ervin moves to full-time; gets $367.7K salary, $160K RSUs

## Summary
- CFO Jeffrey S. Ervin transitioned from part-time to full-time effective December 3, 2025 under new employment agreement.
- Annual base salary set at $367,700; eligible for annual bonus up to 30% of base salary.
- Granted restricted stock units valued at $160,000, vesting in equal installments over three years.
- Severance of six months base salary if terminated without cause, for good reason, or in connection with change of control.

## SEC filing metadata
- accession: 0001213900-25-118989
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390025118989/0001213900-25-118989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390025118989/ea0268404-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-118989
- JSON: https://secwatch.observer/filing/0001213900-25-118989.json
- Plain text: https://secwatch.observer/filing/0001213900-25-118989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.